Chinese pharmaceutical companies gather to go to sea to clean up goods

Source: Beijing business daily August 1, 2016, Chinese pharmaceutical companies are gathering for overseas M & A Recently, Fosun Pharmaceutical announced that it plans to purchase about 86.08% of the equity of India pharmaceutical company gland Pharma Limited (hereinafter referred to as "gland Pharma") through a holding subsidiary of no more than 1261.37 million US dollars (about 8.4 billion yuan) This acquisition is not only the largest foreign acquisition in India since this year, but also a new record for Chinese pharmaceutical companies to go abroad For Fosun Pharmaceutical, this acquisition provides a certain impetus for the group to enter the international generic pharmaceutical market For a long time, Indian pharmaceutical companies have been ahead of Chinese pharmaceutical companies in the process of internationalization in the field of generic drugs According to the data, gland Pharma was founded in 1978, mainly engaged in the production and manufacturing of injection drugs It is the first injection drug manufacturer approved by FDA in India, and has obtained GMP certification in major markets around the world The company's business income mainly comes from the United States and Europe As one of the few companies specializing in the manufacture of injection drugs, gland Pharma is in the leading position among similar companies in the Indian market For the acquisition, Chen Qiyu, chairman of Fosun Pharmaceutical, pointed out in a recent conference call that Fosun Pharmaceutical has been seeking to rapidly enter the global generic pharmaceutical market through M & A in recent years In Fosun's generic medicine business, the injection business has developed well, while gland Pharma has been focusing on the generic medicine market of injection, and is very familiar with the global registration system of injection generic medicine The product has passed the verification of multiple market systems, and the acquisition will help to increase the overall share of both parties in the injection Market At the same time, Fosun Pharmaceutical has the opportunity to export its R & D capabilities to the world through the gland Pharma platform, "including using the global registration capabilities and global quality management capabilities that gland Pharma already has, helping Fosun's domestic products pass the certification in other countries around the world, so that Fosun's domestic R & D products enter the global market through gland pharma." In fact, not only Fosun Pharmaceutical, but also Chinese pharmaceutical companies have made frequent efforts to "clean up" overseas since this year, and all of them have made "big moves" The record of M & A amount has been refreshed faster than ever before At the beginning of this year, sanuo biology announced the acquisition of NIPRO, a diagnostic business company of niplo, a Japanese medical device company, with a transaction of US $273 million Subsequently, on March 29, humanwell pharmaceutical announced the acquisition of two US companies with us $550 million At the same time when Fosun pharmaceutical set a record for Chinese pharmaceutical companies to go abroad and purchase, green leaf pharmaceutical spent about 18 RMB billion to acquire the transdermal drug business of aceno, a Swiss pharmaceutical company In addition, a consortium led by China Resources Group is preparing to acquire a stake in Genesis care, an Australian cancer medical provider, which is said to be worth a $1.7 billion (US $1.3 billion) In July alone, the number of overseas M & as of pharmaceutical companies that disclosed the amount of M & A has reached four, and all of them have considerable scale Cvsource investment data also confirms the high frequency of overseas sales of Chinese pharmaceutical companies this year In the past decade, the average growth rate of overseas investment in Chinese medicine has been only 30%, but in the past six months, there has been a sudden explosion Data shows that in the first quarter of 2016, the transaction amount of China's overseas M & a market tripled compared with the fourth quarter of 2015, reaching US $115.5 billion, which not only exceeds the transaction scale of 2015, but also accounts for nearly 1 / 2 of the global cross-border M & a volume in the first quarter of 2016 To this end, Yue Feng, an expert in the pharmaceutical industry, told reporters that the overseas sales of Chinese pharmaceutical enterprises are largely related to the domestic depressed stock market and the slowdown of economic growth In addition, the domestic pharmaceutical companies that can be listed have been listed, and the targets that can be acquired have been acquired After several rounds, the number of excellent targets for acquisition has been decreasing, which also urges the domestic pharmaceutical companies with sufficient capital flow to explore overseas markets At the same time, Yue Feng also pointed out that most of the Chinese pharmaceutical companies that are currently engaged in overseas M & A have strong capital strength, but when they are engaged in M & A, they still need to "polish their eyes" on the selection of overseas targets In the future, many pharmaceutical companies will choose overseas M & A.